Cited 0 times in
Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강영애 | - |
dc.contributor.author | 김송이 | - |
dc.contributor.author | 김영삼 | - |
dc.contributor.author | 문성우 | - |
dc.contributor.author | 박무석 | - |
dc.contributor.author | 이상훈 | - |
dc.contributor.author | 이수환 | - |
dc.contributor.author | 장준 | - |
dc.contributor.author | 정경수 | - |
dc.contributor.author | 정지예 | - |
dc.contributor.author | 최지수 | - |
dc.date.accessioned | 2021-05-21T17:01:21Z | - |
dc.date.available | 2021-05-21T17:01:21Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182658 | - |
dc.description.abstract | Pirfenidone is an antifibrotic agent that has been proven to slow down the progression of idiopathic pulmonary fibrosis (IPF). The aim of this study was to evaluate the efficacy of low-dose pirfenidone (that is, less than 1200 mg/day). We retrospectively reviewed the medical records of patients with IPF. The patients were divided into the following three groups, those who were not treated with pirfenidone (control) and those who were treated with pirfenidone at doses < 1200 mg/day (low-dose group) and ≥ 1200 mg/day (high-dose group). The adjusted mean changes in forced vital capacity (FVC) in 1 year were - 200.7, - 88.4, and - 94.7 mL in the control, low-dose, and high-dose groups (p = 0.021). The FVC declined more significantly in the control group than in the low-dose and high-dose groups. No significant difference in FVC change was observed between the low-dose and high-dose groups. Dyspepsia, anorexia, and nausea were significantly more frequent in the low-dose than in the high-dose group, suggesting that dose reduction is attributed to gastrointestinal tract-related adverse events. Dose reduction may help patients to better control gastrointestinal tract-related adverse events; continuing taking the medication at low doses is also expected to be effective in reducing the FVC decline. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Nature Publishing Group | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anorexia / complications | - |
dc.subject.MESH | Anti-Inflammatory Agents, Non-Steroidal / administration & dosage* | - |
dc.subject.MESH | Anti-Inflammatory Agents, Non-Steroidal / adverse effects | - |
dc.subject.MESH | Anti-Inflammatory Agents, Non-Steroidal / therapeutic use | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Dyspepsia / complications | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hospitals, University | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Idiopathic Pulmonary Fibrosis / drug therapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Nausea / complications | - |
dc.subject.MESH | Pyridones / administration & dosage* | - |
dc.subject.MESH | Pyridones / adverse effects* | - |
dc.subject.MESH | Pyridones / therapeutic use | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Tertiary Care Centers | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Vital Capacity / drug effects | - |
dc.title | Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Myung Jin Song | - |
dc.contributor.googleauthor | Sung Woo Moon | - |
dc.contributor.googleauthor | Ji Soo Choi | - |
dc.contributor.googleauthor | Sang Hoon Lee | - |
dc.contributor.googleauthor | Su Hwan Lee | - |
dc.contributor.googleauthor | Kyung Soo Chung | - |
dc.contributor.googleauthor | Ji Ye Jung | - |
dc.contributor.googleauthor | Young Ae Kang | - |
dc.contributor.googleauthor | Moo Suk Park | - |
dc.contributor.googleauthor | Young Sam Kim | - |
dc.contributor.googleauthor | Joon Chang | - |
dc.contributor.googleauthor | Song Yee Kim | - |
dc.identifier.doi | 10.1038/s41598-020-77837-x | - |
dc.contributor.localId | A00057 | - |
dc.contributor.localId | A00626 | - |
dc.contributor.localId | A00707 | - |
dc.contributor.localId | A01363 | - |
dc.contributor.localId | A01457 | - |
dc.contributor.localId | A02836 | - |
dc.contributor.localId | A02904 | - |
dc.contributor.localId | A03472 | - |
dc.contributor.localId | A03570 | - |
dc.contributor.localId | A03735 | - |
dc.contributor.localId | A05057 | - |
dc.relation.journalcode | J02646 | - |
dc.identifier.eissn | 2045-2322 | - |
dc.identifier.pmid | 33277557 | - |
dc.contributor.alternativeName | Kang, Young Ae | - |
dc.contributor.affiliatedAuthor | 강영애 | - |
dc.contributor.affiliatedAuthor | 김송이 | - |
dc.contributor.affiliatedAuthor | 김영삼 | - |
dc.contributor.affiliatedAuthor | 문성우 | - |
dc.contributor.affiliatedAuthor | 박무석 | - |
dc.contributor.affiliatedAuthor | 이상훈 | - |
dc.contributor.affiliatedAuthor | 이수환 | - |
dc.contributor.affiliatedAuthor | 장준 | - |
dc.contributor.affiliatedAuthor | 정경수 | - |
dc.contributor.affiliatedAuthor | 정지예 | - |
dc.contributor.affiliatedAuthor | 최지수 | - |
dc.citation.volume | 10 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 21218 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, Vol.10(1) : 21218, 2020-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.